Yeah. I reckon Pharmorage might follow a similar route to Nyrada, and take their new pipeline drugs to an IPO. Personally I like this approach, with NOX holding a big chunk.
But for Veyonda and COVID, should it prove viable? Whatever the quickest route, which I guess is partner and licensing to whoever can run with it.
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results, page-36
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 12.0¢ | 10.5¢ | $84.79K | 771.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 179890 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 349534 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |